Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.41 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.40 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568918 | 0.89 | IDO1 (0.54) | IDO1TDO2CNR2MEN1KMT2A | |
| SCHEMBL10341248 | 0.88 | KDM4E (0.50) | IDO1TDO2CNR2MEN1KMT2A | |
| SCHEMBL10341192 | 0.85 | KDM4E (0.49) | MEN1KMT2AKDM4ECAPN1MAP2K2 | |
| SCHEMBL6050616 | 0.82 | KDM4E (0.56) | MEN1KMT2AKDM4ECAPN1MAP2K2 | |
| SCHEMBL10341232 | 0.82 | KDM4E (0.44) | MEN1KMT2AKDM4ECAPN1ALDH1A1 | |
| SCHEMBL22450681 | 0.80 | KDM4E (0.54) | IDO1TDO2MEN1KMT2AKDM4E | |
| SCHEMBL10341235 | 0.80 | KDM4E (0.45) | MEN1KMT2AKDM4ECAPN1ALDH1A1 | |
| SCHEMBL10341044 | 0.80 | MAP2K2 (0.49) | MEN1KMT2AKDM4ECAPN1MAP2K2 | |
| SCHEMBL10341131 | 0.80 | ALDH1A1 (0.52) | CNR2MEN1KMT2AKDM4ECNR1 | |
| SCHEMBL6050608 | 0.80 | KMT2A (0.49) | CNR2MEN1KMT2AKDM4EMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4855291-A | 1,4dihydroquinoline-3-carboxamides | THE BOOTS COMPANY PLC (GB) | 1989-08-08 | — | — | US | claimed |
| US-6995173-B2 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1355647-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. Alamo Ventures I, LLC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC | 2003-07-10 | — | — | US | disclosed |
| US-6562838-B2 | Providing subject suffering from a symptoms of cardiovascular disease and a purified enantiomer preparation of flosequinan; administering preparation to subject under conditions such that symptom is reduced | R. T. ALAMO VENTURES I, L.L.C. | 2003-05-13 | — | — | US | disclosed |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C, | 2002-10-03 | — | — | US | disclosed |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6458804-B1 | UTILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING QUINOLINONES (AND DERIVATIVES THEREOF) IN PATIENTS WITH SYMPTOMS OF A CENTRAL NERVOUS SYSTEM DISORDER WHO ARE OTHERWISE FREE OF CARDIAC DISEASE AND/OR WHO HAVE NOT BEEN | R.T. ALAMO VENTURESI, LLC | 2002-10-01 | — | — | US | disclosed |
| US-6451813-B1 | Treatment of gastroparesis in certain patient groups | R. T. ALAMO VENTURES I, LLC | 2002-09-17 | — | — | US | disclosed |
| WO-2002058703-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. ALAMO VENTURES I, LLC (US) | 2002-08-01 | — | — | WO | disclosed |
| US-4959363-A | HERPES VIRUS | STERLING DRUG INC. (US) | 1990-09-25 | — | — | US | disclosed |
| EP-0172004-B1 | QUINOLINONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | The Boots Company PLC (GB) | 1990-03-21 | — | — | EP | disclosed |
| US-4855291-A | 1,4dihydroquinoline-3-carboxamides | THE BOOTS COMPANY PLC (GB) | 1989-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | IDO1 143/4885TDO2 1176/4885CNR2 817/4885 |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | PMP22, NLN, SLC6A2 | IDO1 615/4885TDO2 146/4885CNR2 111/4885 |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | IDO1 143/4885TDO2 1176/4885CNR2 817/4885 |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | PMP22, NLN, SLC6A2 | IDO1 615/4885TDO2 146/4885CNR2 111/4885 |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | FABP6, SLC10A2, FABP2 | IDO1 384/4885TDO2 219/4885CNR2 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.